{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T03:14:37Z","timestamp":1787886877945,"version":"build-2784847793"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008990","name":"Science and Technology Department of Zhejiang Province","doi-asserted-by":"publisher","award":["2023ZY1014"],"award-info":[{"award-number":["2023ZY1014"]}],"id":[{"id":"10.13039\/501100008990","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","award":["G2021017004"],"award-info":[{"award-number":["G2021017004"]}],"id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","award":["G20200217005"],"award-info":[{"award-number":["G20200217005"]}],"id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2023KY210"],"award-info":[{"award-number":["2023KY210"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012479","name":"General Research Fund of Shanghai Normal University","doi-asserted-by":"publisher","award":["15102423"],"award-info":[{"award-number":["15102423"]}],"id":[{"id":"10.13039\/501100012479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008856","name":"Zhejiang Provincial Health Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007820","name":"Hangzhou Normal University","doi-asserted-by":"publisher","award":["2022HSDYJSKY008"],"award-info":[{"award-number":["2022HSDYJSKY008"]}],"id":[{"id":"10.13039\/501100007820","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002920","name":"Research Grants Council, University Grants Committee","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002920","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.bcp.2025.117160","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T07:55:50Z","timestamp":1752566150000},"page":"117160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["A novel PARP-ATR dual inhibitor exhibits anti-triple-negative breast cancer activity by inducing excessive DNA damage in the mitotic phase"],"prefix":"10.1016","volume":"241","author":[{"given":"Chen-Chen","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jilong","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nian-Dong","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menglan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng-Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghui","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingrui","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siye","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben C.B.","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3739-0930","authenticated-orcid":false,"given":"Xiang-Yang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bcp.2025.117160_b0005","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","article-title":"Recent advances in therapeutic strategies for triple-negative breast cancer","volume":"15","author":"Yun","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.bcp.2025.117160_b0010","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment landscape of triple-negative breast cancer - expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bcp.2025.117160_b0015","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","article-title":"Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment","volume":"9","author":"Garrido-Castro","year":"2019","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.bcp.2025.117160_b0020","article-title":"Platinum-based systematic therapy in triple-negative breast cancer","volume":"1877","author":"Zhu","year":"2022","journal-title":"BBA-Rev Cancer"},{"issue":"3","key":"10.1016\/j.bcp.2025.117160_b0025","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.3390\/ijms23031665","article-title":"Molecular mechanisms, biomarkers and emerging therapies for chemotherapy resistant TNBC","volume":"23","author":"Ferrari","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.bcp.2025.117160_b0030","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1093\/nar\/gkab136","article-title":"ADP-ribosylation of RNA and DNA: from in vitro characterization to in vivo function","volume":"49","author":"Weixler","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bcp.2025.117160_b0035","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.sbi.2018.11.002","article-title":"PARP family enzymes: regulation and catalysis of the poly(ADP-ribose) posttranslational modification","volume":"53","author":"Langelier","year":"2018","journal-title":"Curr. Opin. Struct. Biol."},{"issue":"8","key":"10.1016\/j.bcp.2025.117160_b0040","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/bjc.2011.382","article-title":"The role of PARP in DNA repair and its therapeutic exploitation","volume":"105","author":"Javle","year":"2011","journal-title":"Brit. J. Cancer"},{"issue":"3","key":"10.1016\/j.bcp.2025.117160_b0045","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.gpb.2016.05.001","article-title":"Functions of PARylation in DNA damage Repair Pathways","volume":"14","author":"Wei","year":"2016","journal-title":"Genom. Proteom. Bioinf."},{"issue":"10","key":"10.1016\/j.bcp.2025.117160_b0050","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/s41573-020-0076-6","article-title":"Poly(ADP-ribose) polymerase inhibition: past, present and future","volume":"19","author":"Curtin","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.bcp.2025.117160_b0055","doi-asserted-by":"crossref","first-page":"176","DOI":"10.4248\/IJOS11064","article-title":"DNA repair and synthetic lethality","volume":"3","author":"Guo","year":"2011","journal-title":"Int. J. Oral Sci."},{"issue":"14","key":"10.1016\/j.bcp.2025.117160_b0060","doi-asserted-by":"crossref","DOI":"10.1172\/JCI181062","article-title":"BRCAness, DNA gaps, and gain and loss of PARP inhibitor-induced synthetic lethality","volume":"134","author":"Li","year":"2024","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2025.117160_b0065","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00044-025-03375-8","article-title":"Olaparib research update: mechanism, structure and clinical trials","volume":"34","author":"Che","year":"2025","journal-title":"Med. Chem. Res."},{"issue":"2","key":"10.1016\/j.bcp.2025.117160_b0070","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/modpathol.2010.200","article-title":"Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists","volume":"24","author":"Badve","year":"2011","journal-title":"Mod. Pathol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117160_b0075","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13053-022-00242-0","article-title":"Efficacy of different neoadjuvant treatment regimens in BRCA-mutated triple negative breast cancer: a systematic review and meta-analysis","volume":"20","author":"Caramelo","year":"2022","journal-title":"Hered. Cancer Clin. Pract."},{"issue":"8","key":"10.1016\/j.bcp.2025.117160_b0080","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nrm2450","article-title":"ATR: an essential regulator of genome integrity","volume":"9","author":"Cimprich","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"6404","key":"10.1016\/j.bcp.2025.117160_b0085","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1126\/science.aap9346","article-title":"An intrinsic S\/G2 checkpoint enforced by ATR","volume":"361","author":"Saldivar","year":"2018","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.bcp.2025.117160_b0090","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.devcel.2022.02.013","article-title":"Chk1 dynamics in G2 phase upon replication stress predict daughter cell outcome","volume":"57","author":"Lebrec","year":"2022","journal-title":"Dev. Cell"},{"issue":"6","key":"10.1016\/j.bcp.2025.117160_b0095","article-title":"Genome stability requires p53","volume":"6","author":"Eischen","year":"2016","journal-title":"CSH Perspect Med."},{"issue":"9","key":"10.1016\/j.bcp.2025.117160_b0100","article-title":"DNA damage Sensing by the ATM and ATR Kinases","volume":"5","author":"Mar\u00e9chal","year":"2013","journal-title":"CSH Perspect Biol."},{"issue":"3","key":"10.1016\/j.bcp.2025.117160_b0105","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.tibs.2010.09.005","article-title":"ATR: a master conductor of cellular responses to DNA replication stress","volume":"36","author":"Flynn","year":"2011","journal-title":"Trends Biochem. Sci"},{"issue":"1","key":"10.1016\/j.bcp.2025.117160_b0110","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s13045-021-01169-0","article-title":"Targeting mutant p53 for cancer therapy: direct and indirect strategies","volume":"14","author":"Hu","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.bcp.2025.117160_b0115","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.7150\/thno.81847","article-title":"Role of p53 in breast cancer progression: an insight into p53 targeted therapy","volume":"13","author":"Marvalim","year":"2023","journal-title":"Theranostics"},{"issue":"6","key":"10.1016\/j.bcp.2025.117160_b0120","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3390\/cancers16061139","article-title":"Triple-negative breast cancer and emerging therapeutic strategies: ATR and CHK1\/2 as promising targets","volume":"16","author":"Sofianidi","year":"2024","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.bcp.2025.117160_b0125","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1158\/0008-5472.CAN-23-0628","article-title":"BRCAness, Homologous recombination deficiencies, and synthetic lethality","volume":"83","author":"Murai","year":"2023","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2025.117160_b0130","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1038\/s41467-020-17127-2","article-title":"Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.bcp.2025.117160_b0135","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1101\/gad.290957.116","article-title":"ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells","volume":"31","author":"Yazinski","year":"2017","journal-title":"Gene. Dev."},{"issue":"6","key":"10.1016\/j.bcp.2025.117160_b0140","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/0008-5472.CAN-21-2997","article-title":"ATR inhibitor AZD6738 (Ceralasertib) exerts antitumor activity as a monotherapy and in combination with chemotherapy and the PARP inhibitor Olaparib","volume":"82","author":"Wilson","year":"2022","journal-title":"Cancer Res."},{"issue":"25","key":"10.1016\/j.bcp.2025.117160_b0145","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1038\/s41388-020-1328-y","article-title":"Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells","volume":"39","author":"Lloyd","year":"2020","journal-title":"Oncogene"},{"issue":"23","key":"10.1016\/j.bcp.2025.117160_b0150","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.1158\/1078-0432.CCR-23-1696","article-title":"Olaparib and Ceralasertib (AZD6738) in patients with triple-negative advanced breast cancer: results from cohort E of the plasmaMATCH trial (CRUK\/15\/010)","volume":"29","author":"Ring","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.bcp.2025.117160_b0155","doi-asserted-by":"crossref","first-page":"4950","DOI":"10.1021\/acs.jmedchem.4c00090","article-title":"Design, synthesis, and structure\u2013activity relationship of novel pyridazinone-based PARP7\/HDACs dual inhibitors for elucidating the relationship between antitumor immunity and HDACs inhibition","volume":"67","author":"Duan","year":"2024","journal-title":"J. Med. Chem."},{"issue":"13","key":"10.1016\/j.bcp.2025.117160_b0160","doi-asserted-by":"crossref","first-page":"10848","DOI":"10.1021\/acs.jmedchem.4c00296","article-title":"Novel bifunctional conjugates targeting PD-L1\/PARP7 as dual immunotherapy for potential cancer treatment","volume":"67","author":"Gao","year":"2024","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2025.117160_b0165","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1093\/nar\/gkab020","article-title":"Dynamics of the HD regulatory subdomain of PARP-1; substrate access and allostery in PARP activation and inhibition","volume":"49","author":"Ogden","year":"2021","journal-title":"Nucleic Acids Res."},{"issue":"11","key":"10.1016\/j.bcp.2025.117160_b0170","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/j.jmb.2017.04.006","article-title":"Rationally designed PI3K\u03b1 mutants to mimic ATR and their use to understand binding specificity of ATR inhibitors","volume":"429","author":"Lu","year":"2017","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bcp.2025.117160_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106535","article-title":"Design, synthesis, and biological evaluation of pyrido[3,2-d]pyrimidine derivatives as novel ATR inhibitors","volume":"136","author":"Duan","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bcp.2025.117160_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115370","article-title":"Discovery of Thieno[3,2-d]pyrimidine derivatives as potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) kinase","volume":"255","author":"Duan","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"7","key":"10.1016\/j.bcp.2025.117160_b0185","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nchembio.573","article-title":"Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR","volume":"7","author":"Reaper","year":"2011","journal-title":"Nat. Chem. Biol."},{"issue":"5","key":"10.1016\/j.bcp.2025.117160_b0190","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3390\/cancers12051095","article-title":"ATR inhibition potentiates PARP inhibitor cytotoxicity in high risk neuroblastoma cell lines by multiple mechanisms","volume":"12","author":"Southgate","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.bcp.2025.117160_b0195","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-071674","article-title":"Advances in systemic therapies for triple negative breast cancer","volume":"381","author":"Leon-Ferre","year":"2023","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.bcp.2025.117160_b0200","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12929-022-00870-7","article-title":"Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors","volume":"29","author":"Chu","year":"2022","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.bcp.2025.117160_b0205","doi-asserted-by":"crossref","DOI":"10.34133\/2021\/9760398","article-title":"Tumor microenvironment-specific chemical internalization for enhanced gene therapy of metastatic breast cancer","volume":"2021","author":"Zhou","year":"2021","journal-title":"Research"},{"key":"10.1016\/j.bcp.2025.117160_b0210","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.12688\/f1000research.7563.2","article-title":"Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences","volume":"4","author":"Soneson","year":"2016","journal-title":"F1000Res"},{"issue":"12","key":"10.1016\/j.bcp.2025.117160_b0215","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225004253?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225004253?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T13:30:10Z","timestamp":1767360610000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225004253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":43,"alternative-id":["S0006295225004253"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117160","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel PARP-ATR dual inhibitor exhibits anti-triple-negative breast cancer activity by inducing excessive DNA damage in the mitotic phase","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117160","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117160"}}